OMIC vs. RPID, CARA, HLTH, AXDX, TLIS, PRPO, PRE, BNGO, APLM, and DARE
Should you be buying Singular Genomics Systems stock or one of its competitors? The main competitors of Singular Genomics Systems include Rapid Micro Biosystems (RPID), Cara Therapeutics (CARA), Cue Health (HLTH), Accelerate Diagnostics (AXDX), Talis Biomedical (TLIS), Precipio (PRPO), Prenetics Global (PRE), Bionano Genomics (BNGO), Apollomics (APLM), and Daré Bioscience (DARE). These companies are all part of the "medical" sector.
Rapid Micro Biosystems (NASDAQ:RPID) and Singular Genomics Systems (NASDAQ:OMIC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.
In the previous week, Singular Genomics Systems had 9 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 9 mentions for Singular Genomics Systems and 0 mentions for Rapid Micro Biosystems. Singular Genomics Systems' average media sentiment score of 0.00 beat Rapid Micro Biosystems' score of -0.04 indicating that Rapid Micro Biosystems is being referred to more favorably in the media.
Rapid Micro Biosystems has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Singular Genomics Systems has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.
52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 65.8% of Singular Genomics Systems shares are owned by institutional investors. 30.4% of Rapid Micro Biosystems shares are owned by insiders. Comparatively, 22.2% of Singular Genomics Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Singular Genomics Systems has a consensus price target of $0.63, suggesting a potential upside of 61.33%. Given Rapid Micro Biosystems' higher probable upside, analysts clearly believe Singular Genomics Systems is more favorable than Rapid Micro Biosystems.
Rapid Micro Biosystems has higher revenue and earnings than Singular Genomics Systems. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.
Rapid Micro Biosystems has a net margin of -224.73% compared to Rapid Micro Biosystems' net margin of -3,863.90%. Singular Genomics Systems' return on equity of -42.25% beat Rapid Micro Biosystems' return on equity.
Singular Genomics Systems received 9 more outperform votes than Rapid Micro Biosystems when rated by MarketBeat users. Likewise, 46.43% of users gave Singular Genomics Systems an outperform vote while only 26.67% of users gave Rapid Micro Biosystems an outperform vote.
Summary
Rapid Micro Biosystems and Singular Genomics Systems tied by winning 8 of the 16 factors compared between the two stocks.
Get Singular Genomics Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Singular Genomics Systems Competitors List
Related Companies and Tools
